SCHEMBL3348627

SCHEMBL3348627

Brc1cncc(-c2ccc3[nH]ccc3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 2/20 0.54
PIP4K2B P78356 2/20 0.54
CYP2A6 P11509 2/20 0.53
AHR P35869 1/20 0.53
NR4A2 P43354 1/20 0.53
NPC1 O15118 1/20 0.53
FYN P06241 1/20 0.51
CYP11B1 P15538 3/20 0.50
CYP11B2 P19099 3/20 0.50
CYP17A1 P05093 1/20 0.50
MAP3K11 Q16584 2/20 0.49
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
CLK1 P49759 1/20 0.44
DYRK1A Q13627 1/20 0.44
DYRK2 Q92630 1/20 0.44
DYRK1B Q9Y463 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13354456 0.81 PIP4K2A (0.58) PIP4K2APIP4K2BNPC1FYNCYP11B1
SCHEMBL6655349 0.80 NPC1 (0.59) PIP4K2APIP4K2BCYP2A6AHRNR4A2
SCHEMBL3462787 0.79 AHR (0.70) PIP4K2APIP4K2BCYP2A6AHRNR4A2
SCHEMBL5850255 0.78 NPC1 (0.79) CYP2A6AHRNR4A2NPC1FYN
SCHEMBL3708145 0.77 CYP2A6 (0.57) PIP4K2APIP4K2BCYP2A6NPC1FYN
SCHEMBL31317869 0.77 CYP11B1 (0.63) PIP4K2APIP4K2BNPC1FYNCYP11B1
SCHEMBL13322392 0.77 PIP4K2A (0.54) PIP4K2APIP4K2BNPC1FYNCYP11B1
SCHEMBL12680497 0.77 NPC1 (0.56) CYP2A6AHRNR4A2NPC1FYN
SCHEMBL6657347 0.75 NPC1 (0.64) PIP4K2APIP4K2BCYP2A6NPC1FYN
SCHEMBL3956542 0.74 CYP17A1 (0.76) PIP4K2APIP4K2BCYP2A6AHRNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 CN disclosed
WO-2012002577-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF 富士フイルム株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK PIP4K2A 1906/4885PIP4K2B 1669/4885CYP2A6 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.